Biohaven Pharmaceutical Holding Company Ltd. (BHVN) and Pfizer Inc. (PFE) have completed the collaboration transaction for commercialization of Rimegepant and Zavegepant outside U.S. These agreements have become effective following the receipt of required regulatory approvals.
In connection with the closing, Pfizer made an upfront payment to Biohaven of $500 million, consisting of $150 million cash and $350 million in the purchase of Biohaven equity. At close, Pfizer will own 3% of Biohaven.
Biohaven is also eligible to receive up to $740 million in future milestones.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.